Full Press Release Details
Eidos Therapeutics Initiates Phase 2 Clinical Trial For AG10 Targeting Transthyretin Amyloidosis Cardiomyopathy.
BBIO
Eidos Therapeutics Initiates Phase 2 Clinical Trial For AG10 Targeting Transthyretin Amyloidosis Cardiomyopathy
Key Takeaway: Eidos Therapeutics Initiates Phase 2 Clinical Trial For AG10 Targeting Transthyretin Amyloidosis Cardiomyopathy